US OKs first treatment for haemophagocytic lymphohistiocytos
US regulators have approved Swedish Orphan Biovitrum (Sobi) and Novimmune’s Gamifant as the first treatment for the rare disorder primary haemophagocytic lymphohistiocytosis.
Read More
Tag: HLH
Novimmune submits lead drug emapalumab in Europe
Swiss biotech Novimmune has submitted a marketing application in Europe seeking permission to market its lead compound emapalumab for the treatment of patients with primary Hemophagocytic Lymphohistiocytosis (HLH).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
